|
Description
Primary care diabetes teams need no reminder that they operate in a therapeutic paradox. We have good evidence for the importance of maintaining tight glycaemic control (UKPDS Group, 1998) and now, through the nGMS contract, a financial incentive to do so. Yet helping our patients with type 2 diabetes achieve tight targets can be a challenging process: involving prescribing combinations of hypoglycaemic agents; negotiating side effects with patients; and trying to ensure adherence to increasingly complex regimens. Against this background, the imminent availability of newer hypoglycaemic agents is both welcome in expanding our therapeutic armamentarium, but also adds a further layer of complexity to already challenging prescribing scenarios.
[ILLUSTRATION OMITTED]
This issue of Diabetes & Primary Care includes clear descriptions... |
More articles from Diabetes and Primary Care
When to consider antiobesity drugs or bariatric surgery., June 22, 2007
A spoonful of education helps the medicine go down., June 22, 2007
Diabetes specialism: interesting times?(GPSI Focus), June 22, 2007
The changing face of diabetes specialist services: making it work.(GPS..., June 22, 2007
The first national conference for intermediate diabetes care teams--wi..., June 22, 2007
Looking for additional articles?
Click here
to search our database of over 3 million articles.
|
